The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

BACKGROUND: The VeriStrat test is a serum proteomic signature originally discovered in non-responders to second line gefitinib treatment and subsequently used to predict differential benefit from erlotinib versus chemotherapy in previously treated advanced non-small cell lung cancer (NSCLC). Multipl...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Fidler, Mary Jo, Fhied, Cristina L., Roder, Joanna, Basu, Sanjib, Sayidine, Selina, Fughhi, Ibtihaj, Pool, Mark, Batus, Marta, Bonomi, Philip, Borgia, Jeffrey A.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5861613/
https://ncbi.nlm.nih.gov/pubmed/29558888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4193-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky